TR200701870T1 - İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem. - Google Patents

İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem.

Info

Publication number
TR200701870T1
TR200701870T1 TR2007/01870T TR200701870T TR200701870T1 TR 200701870 T1 TR200701870 T1 TR 200701870T1 TR 2007/01870 T TR2007/01870 T TR 2007/01870T TR 200701870 T TR200701870 T TR 200701870T TR 200701870 T1 TR200701870 T1 TR 200701870T1
Authority
TR
Turkey
Prior art keywords
crystalline form
imatinib mesylate
preparation
stable crystalline
methyl
Prior art date
Application number
TR2007/01870T
Other languages
English (en)
Inventor
Laxminarayan Pathi Srinivas
Ramchandra Rao Dharmaraj
Narayanrao Kankan Rajendra
Puppala Ravikumar
Original Assignee
Cipla Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Limited filed Critical Cipla Limited
Publication of TR200701870T1 publication Critical patent/TR200701870T1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Buluş, 4-(4-metil piperazın-1-il metil)-N-[4-metıl-3-(4-piridin-3-il) pirimidin-2-il amino) fenil]-benzamidin metan sülfonik asit ilave tuzunun (İmatinib mesilat) kararlı, higroskopik olmayan alfa kristalin formuna ilişkindir. Kristalin formun hazırlanması için işlem de açıklanmıştır.
TR2007/01870T 2004-09-02 2005-09-02 İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem. TR200701870T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN951MU2004 2004-09-02

Publications (1)

Publication Number Publication Date
TR200701870T1 true TR200701870T1 (tr) 2007-05-21

Family

ID=35385539

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2007/01870T TR200701870T1 (tr) 2004-09-02 2005-09-02 İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem.

Country Status (4)

Country Link
US (1) US8269003B2 (tr)
KR (1) KR101348625B1 (tr)
TR (1) TR200701870T1 (tr)
WO (1) WO2006024863A1 (tr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006048890A1 (en) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
JP2009506014A (ja) * 2005-08-26 2009-02-12 ノバルティス アクチエンゲゼルシャフト イマチニブメシレートのデルタおよびイプシロン結晶形
AU2006316823A1 (en) 2005-11-25 2007-05-31 Novartis Ag F,G,H,I and K crystal forms of imatinib mesylate
US7977348B2 (en) 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US8067421B2 (en) 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
WO2007136510A2 (en) 2006-04-27 2007-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha
US20060223816A1 (en) * 2006-05-08 2006-10-05 Chemagis Ltd. Imatinib mesylate alpha form and production process therefor
EP1988089A1 (en) 2006-10-26 2008-11-05 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
MX2010003200A (es) * 2007-09-25 2010-04-30 Teva Pharma Composiciones de imatibnib estables.
US7947699B2 (en) 2008-01-10 2011-05-24 Actavis Group Ptc Ehf Anhydrous amorphous imatinib mesylate
EP2291366A4 (en) * 2008-05-26 2012-06-06 Reddys Lab Ltd Dr PREPARATION OF IMATINIB MESYLATE
US20100330130A1 (en) 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
WO2011100282A2 (en) * 2010-02-09 2011-08-18 Dr. Reddy's Laboratories Ltd. Imatinib mesylate polymorphs
EP2536707A1 (en) 2010-02-15 2012-12-26 Reliance Life Sciences Pvt., Ltd. Process for the preparation of alpha form of imatinib mesylate
CA2792472A1 (en) 2010-03-15 2011-09-22 Natco Pharma Limited Process for the preparation of highly pure crystalline imatinib base
EP2552447A4 (en) * 2010-03-29 2013-09-11 Hetero Research Foundation STABLE PHARMACEUTICAL COMPOSITION OF IMATINIB
US8609842B2 (en) 2010-04-23 2013-12-17 Fujian South Pharmaceutical Co., Ltd. Method for synthesizing Imatinib
WO2011158255A1 (en) * 2010-06-16 2011-12-22 Aptuit Laurus Private Limited Process for preparation of stable imatintb mesylate alpha form
EA024088B1 (ru) 2010-06-18 2016-08-31 КРКА, д.д., НОВО МЕСТО α-ФОРМА МЕЗИЛАТА ИМАТИНИБА, СПОСОБЫ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЁ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
US20130203990A1 (en) * 2010-07-29 2013-08-08 Dr. Reddy's Laboratories, Inc. Process for the preparation of imatinib mesylate
CN102477031B (zh) * 2010-11-30 2015-07-15 浙江九洲药业股份有限公司 一种甲磺酸伊马替尼α晶型的制备方法
CN102190649B (zh) * 2011-03-28 2013-01-02 齐鲁天和惠世制药有限公司 一种制备α型甲磺酸伊马替尼的方法
JP2014509642A (ja) 2011-03-31 2014-04-21 アイエヌディー−スイフト ラボラトリーズ リミテッド イマチニブ及びそのメシル酸塩の生成のための改良方法
ITMI20111309A1 (it) * 2011-07-14 2013-01-15 Italiana Sint Spa Procedimento di preparazione di imatinib mesilato
IN2012DE00728A (tr) 2012-03-13 2015-08-21 Fresenius Kabi Oncology Ltd
CN103467446A (zh) * 2012-06-05 2013-12-25 广东东阳光药业有限公司 一种甲磺酸伊马替尼α晶型的制备方法
KR101242955B1 (ko) * 2012-06-25 2013-03-12 제일약품주식회사 이마티닙 메실레이트 결정형 α의 제조 방법
CN103570674A (zh) * 2012-08-04 2014-02-12 浙江九洲药业股份有限公司 一种甲磺酸伊马替尼α晶型的制备方法
US9439903B2 (en) 2012-10-25 2016-09-13 Cadila Healthcare Limited Process for the preparation of amorphous imatinib mesylate
CN103044396A (zh) * 2012-12-14 2013-04-17 浙江华海药业股份有限公司 一种甲磺酸伊马替尼α晶型晶体的制备方法
CN103058991A (zh) * 2012-12-28 2013-04-24 南京艾德凯腾生物医药有限责任公司 一种α晶型甲磺酸伊马替尼的制备方法
EP3007699A4 (en) * 2013-06-12 2017-01-18 Shilpa Medicare Limited Crystalline imatinib mesylate process
EP2927223B1 (en) 2014-04-04 2016-06-29 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for preparing imatinib and salts thereof, free of genotoxic impurity f
WO2015188243A1 (en) * 2014-06-10 2015-12-17 Cristália Produtos Químicos Farmacêuticos Ltda PROCESS FOR PREPARING IMATINIB AND IMATINIB MESYLATE NON-NEEDLE SHAPED α2 FORM
EP3274348A4 (en) * 2015-03-26 2018-08-22 Unichem Laboratories Limited Process of preparing potassium salt of azilsartan medoxomil
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (tr) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB2398565A (en) 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
WO2004106326A1 (en) 2003-06-02 2004-12-09 Hetero Drugs Limited Novel polymorphs of imatinib mesylate
PL1720853T3 (pl) * 2004-02-11 2016-06-30 Natco Pharma Ltd Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania
UA84462C2 (ru) 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой

Also Published As

Publication number Publication date
US20070265288A1 (en) 2007-11-15
KR101348625B1 (ko) 2014-01-07
US8269003B2 (en) 2012-09-18
KR20070063524A (ko) 2007-06-19
WO2006024863A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
UA84462C2 (ru) Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
PE20121476A1 (es) Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r
TR200000060T2 (tr) Bir N-fenil-2-pirimidinamin türevinin kristal modifikasyonu ve yapım işlemleri ve kullanımı.
PE20040647A1 (es) Inhibidores de cinasas de tirosina
PE20170697A1 (es) Indazoles sustituidos con benzilo como inhibidores de bub1
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
NO20074287L (no) Pyrazin-2-karboksamidderivater som mGluR5 antagonister
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
EA201071019A1 (ru) Кристаллические формы производных фениламинопиримидина
CY1109907T1 (el) Διεργασια για την παρασκευη 2-αμινοθειαζολο-5- αρωματικων καρβοξαμιδιων ως αναστολεις κινασων
EA200701245A1 (ru) Производные 2,4(4,6)-пиримидинов
PE20091073A1 (es) Derivados de isoxazolo-piridina
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
TW200637550A (en) Thiazole-4-carboxamide derivatives as mGluR5 antagonists
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
PE20120937A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales
IL229395A0 (en) Modified release of4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide solubilized using organic acids
PE20120320A1 (es) Pirazinilpirazoles
NO20082684L (no) F-, G-, H-, I- og K-krystallformer av imatinibmesylat
PE20151601A1 (es) Compuestos novedosos de pirimidina y piridina y su uso
MA28685B1 (fr) Derives de la quinazolinone, antagonistes de la vanilloide
BRPI0507464A (pt) formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n[4-metil-3-((4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida
PE20081735A1 (es) Derivados de 1-oxa-3[4,5]decan-2-ona en el tratamiento de trastornos alimenticios
DE602005023658D1 (de) Verfahren zur herstellung von imatinib-base
PE20070111A1 (es) Aminopirimidinas como moduladores de quinasas